Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Change in Receivables: 2024-2025

Historic Change in Receivables for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to -$3.0 million.

  • Day One Biopharmaceuticals' Change in Receivables fell 573.92% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year change of. This contributed to the annual value of $13.9 million for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Change in Receivables stood at -$3.0 million for Q3 2025, which was down 284.02% from $1.6 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Change in Receivables high stood at $9.1 million for Q2 2024, and its period low was -$3.0 million during Q3 2025.
  • Its 2-year average for Change in Receivables is $2.8 million, with a median of $2.9 million in 2025.
  • Data for Day One Biopharmaceuticals' Change in Receivables shows a maximum YoY slumped of 573.92% (in 2025) over the last 5 years.
  • Over the past 2 years, Day One Biopharmaceuticals' Change in Receivables (Quarterly) stood at $5.2 million in 2024, then slumped by 573.92% to -$3.0 million in 2025.
  • Its Change in Receivables was -$3.0 million in Q3 2025, compared to $1.6 million in Q2 2025 and $4.2 million in Q1 2025.